US2356062A - Therapeutic composition - Google Patents

Therapeutic composition Download PDF

Info

Publication number
US2356062A
US2356062A US429371A US42937142A US2356062A US 2356062 A US2356062 A US 2356062A US 429371 A US429371 A US 429371A US 42937142 A US42937142 A US 42937142A US 2356062 A US2356062 A US 2356062A
Authority
US
United States
Prior art keywords
composition
ozonized
oxygen
therapeutic composition
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US429371A
Inventor
Charles C Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LATIMER LAB Inc
LATIMER LABORATORY Inc
Original Assignee
LATIMER LAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LATIMER LAB Inc filed Critical LATIMER LAB Inc
Priority to US429371A priority Critical patent/US2356062A/en
Application granted granted Critical
Publication of US2356062A publication Critical patent/US2356062A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/24Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
    • A01N43/26Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/12Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof

Definitions

  • the present invention is concerned with compositions of the type that function by the release of nascent oxygen under body heat .for sustained therapeutic action.
  • Such ozonized oil is furthermore relatively immiscible with other oils such as unozonized olive oil or mineral oil, so that dilution of 'full strength ozonized oil gives rise to mechanical difficulties, aside from the reduced therapeutic eiiectiveness of the diluted product.
  • eign material such as solubilizing agents, in an efiort to promote the mixture of the ozoniz-ed oil .with diluent is apt to lead to other complications,
  • substantially pure glycerinetrioleate is ozonized by any of the conventional ozonizing processes, desirably by s'lent electric discharge.
  • the double bondofeach of the three acid radicals which esterify the glycerol is thus ozonized
  • the compound when ozonized to the maximum extent practically attainable on a commercial scale, may. contain as high as 1.85 per cent of available oxygen thus added to the molecule of glycerol trioleate, and this is fully nity per cent higher than the corresponding maximum 1. e. '1. per cent of oxygen capable of being combined with olive oil.
  • the efiectiveness of the composition is thus considerably greater than that of ozonized olive oil,
  • Another object is to provide a composition for the above purpose,.which is suiilciently viscous to stay in place for effective action on the organ or upon the-tissue to. which it is applied, which has no objectionableodor, and which; while it efiectively releasesnascent oxygen when applied to body tissues, will retain its effectiveness ror' all practical purposes, when sealed'in a jar or flask in storage at normal "room temperature for a period as much astwo years.
  • the ozonized glycerol trioleate even with its high apart from the vitally important. circumstance that it is non-irritating to delicate tissues such By reason of its high added oxygen ingly 'ozonized olive'oil, sothat it will more reliably' remain in situ on the organ or on the tiseadily flowing therefrom and will function for hours by the a slow release of therapeutic nascent oxygen given up bythe molecule under body heat.
  • the composition has no objectionable odor and need therefore not be masked and the mechanical diflicul'ty of admixing essential oils therewith and the dilution-and other objections incurred by such masking are obviated.
  • the composition is germicidal, fungicidal and nasal and vaginal tracts, the sinuses and the like.
  • the composition produces exceptionally meritorious results in the treatment of secondary or tertiary burns.
  • Another application is as a vermifuge.
  • the composition may be solidified suftory purposes, by admixing the samewith hydrogenated cotton seed oil or the like.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented Aug. 15, 1944 THERAPEUTIC comosrrron Charles 0. JohnsomNew York, N. Y., assignor to Inc., New York, N. -Y., a
Latimer Laboratory,
York
No Drawing. Application February 3, 1942,
I corporation of New Serial No.
1 Claim.
The present invention is concerned with compositions of the type that function by the release of nascent oxygen under body heat .for sustained therapeutic action.
As conducive to a clear understanding of the invention, it is noted that while the maximum available oxygen content of ozonized olive oillor practical purposes, is but 1.3 per cent, yet it is not feasible to use that composition full strength on delicate tissues. Such composition will cause a severe and painful stinging sensation when applied to the nasal passages for instance,
unless the oxygen content is maintained at or below .5 per cent, 1. e., not more than one-third full strength. Moreover, the completely ozonized olive oil has objectionable'odors that are not easy to mask, and the attempt to mask the s to other difficulties. v
Such ozonized oilis furthermore relatively immiscible with other oils such as unozonized olive oil or mineral oil, so that dilution of 'full strength ozonized oil gives rise to mechanical difficulties, aside from the reduced therapeutic eiiectiveness of the diluted product. eign material such as solubilizing agents, in an efiort to promote the mixture of the ozoniz-ed oil .with diluent is apt to lead to other complications,
n the. other hand, where it is attempted to ozonize the olive oil to a lesser degree, within the V limits that admit of painless application to delicate tissues the critical control of such limited e leads The introduction of forembodiment, substantially pure glycerinetrioleate is ozonized by any of the conventional ozonizing processes, desirably by s'lent electric discharge. The double bondofeach of the three acid radicals which esterify the glycerol is thus ozonized,
three oxygen atoms bridging between the carbon atoms that flankthe double bond on each of the three acid radicals.
The compound, when ozonized to the maximum extent practically attainable on a commercial scale, may. contain as high as 1.85 per cent of available oxygen thus added to the molecule of glycerol trioleate, and this is fully nity per cent higher than the corresponding maximum 1. e. '1. per cent of oxygen capable of being combined with olive oil. I The efiectiveness of the composition is thus considerably greater than that of ozonized olive oil,
. as those of the nasal passages even when used sues to which it is applied, without r .addition of oxygen to the molecule-is dimcult and the stability of the product on storage is relatively low.
It is among the objects of the present invention to provide a composition with an oxygen content capable of being slowly released in nascent vform under body heat, which oxygen content shall be much higher than the maximum attainable with olive oil, and which-composition shall yet be non-irritating in its full concentration.
even'when applied to the most'delicate tissues of the human body such, for instance, as the nasal passages.
Another object is to provide a composition for the above purpose,.which is suiilciently viscous to stay in place for effective action on the organ or upon the-tissue to. which it is applied, which has no objectionableodor, and which; while it efiectively releasesnascent oxygen when applied to body tissues, will retain its effectiveness ror' all practical purposes, when sealed'in a jar or flask in storage at normal "room temperature for a period as much astwo years.
0 the ozonized glycerol trioleate even with its high apart from the vitally important. circumstance that it is non-irritating to delicate tissues such By reason of its high added oxygen ingly 'ozonized olive'oil, sothat it will more reliably' remain in situ on the organ or on the tiseadily flowing therefrom and will function for hours by the a slow release of therapeutic nascent oxygen given up bythe molecule under body heat. The composition has no objectionable odor and need therefore not be masked and the mechanical diflicul'ty of admixing essential oils therewith and the dilution-and other objections incurred by such masking are obviated.
Except for the desiredrelease of nascent oxygen there is no break-down of the molecular structure of the composition during use. No foreign matter such as ketones, aldehydes or thelike, even small proportions of which would be irritating is present or is formedin the course of theuse of thecomposition.
While the pr ce 0! such stable saturated oils in the composition as may be-miscible with the ozonized glycerlne trioleate would theoretionly do no particular harm hysiologically, lution would be incurred, .so that the available nascent oxygen is of-lowe ercentage andthe composition is accordingly less eflective, without advantages, since as above noted,
' av ble nascent oxygen content is non-irritating to delicate tissu s The relatively viscous composition constituting According to theinventiomin one. practical the medicament or the present invention will not deteriorate materially when stored in flas or jars at norma1 room temperatures.
The composition is germicidal, fungicidal and nasal and vaginal tracts, the sinuses and the like. The composition produces exceptionally meritorious results in the treatment of secondary or tertiary burns. Another application is as a vermifuge. The composition may be solidified suftory purposes, by admixing the samewith hydrogenated cotton seed oil or the like.
Esters of fatty acids with two double bonds,
tionable from this standpoint. The ozonization of oils that contain such ingredients even in small proportions, especially if they also contain oxidizable coloring and flavoring matter is not some of them tend to explode on ozonizing.
As many changes could be made in the above out. polymerization, oxidation or decomposition.
CHARLES C. JOHNSON.
US429371A 1942-02-03 1942-02-03 Therapeutic composition Expired - Lifetime US2356062A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US429371A US2356062A (en) 1942-02-03 1942-02-03 Therapeutic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US429371A US2356062A (en) 1942-02-03 1942-02-03 Therapeutic composition

Publications (1)

Publication Number Publication Date
US2356062A true US2356062A (en) 1944-08-15

Family

ID=23702952

Family Applications (1)

Application Number Title Priority Date Filing Date
US429371A Expired - Lifetime US2356062A (en) 1942-02-03 1942-02-03 Therapeutic composition

Country Status (1)

Country Link
US (1) US2356062A (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451480A (en) * 1982-04-16 1984-05-29 James Howard Brown Method of treating acne using ozonized materials
US4591602A (en) * 1982-04-16 1986-05-27 James H. Brown Ozonide esters and topical compositions containing same
WO1989012626A1 (en) * 1988-06-24 1989-12-28 Stephen Herman Ozonides of terpenes and their medical uses
WO1990014764A1 (en) * 1989-06-08 1990-12-13 Stephen Herman Method for treating viral infection
US5086076A (en) * 1988-06-24 1992-02-04 Stephen Herman Antiviral pharmaceutical compositions comprising a terpene ozonide
US5093326A (en) * 1989-06-19 1992-03-03 Stephen Herman Repellant compositions
US5126376A (en) * 1988-06-24 1992-06-30 Stephen Herman Method for treating viral infection using topical administration
US5190977A (en) * 1988-06-24 1993-03-02 Stephen Herman Antiviral compositions
US5190979A (en) * 1988-06-24 1993-03-02 Stephen Herman Ozonides of terpenes and their medical uses
WO1993012654A1 (en) * 1991-12-24 1993-07-08 Stephen Herman Medical uses of trioxolane and diperoxide compounds
US5260342A (en) * 1988-06-24 1993-11-09 Stephen Herman Method for treating viral infection parenterally
US5270344A (en) * 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
US5364879A (en) * 1988-06-24 1994-11-15 Cliveden Ltd. Medical uses of trioxolane and diperoxide compounds
US5785988A (en) * 1996-05-10 1998-07-28 Fust; Charles A. Composition for freshening nostrils and sinus cavities
US6344210B2 (en) 1996-05-10 2002-02-05 Charles A. Fust Composition for freshening nostrils and sinus cavities
WO2003085072A1 (en) * 2002-04-08 2003-10-16 Centro Nacional De Investigaciones Cientificas (Cnic) Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
US20050084454A1 (en) * 2003-10-14 2005-04-21 Sinofresh Healthcare, Inc. Compositions and methods for cleaning nasal cavities
JP2005112798A (en) * 2003-10-08 2005-04-28 Atsuya Ogata External therapeutic agent and therapeutic method for treating inflammation or wound of animal
JP2005112796A (en) * 2003-10-08 2005-04-28 Toshiaki Miura Antiinflammatory external preparation
JP2005112797A (en) * 2003-10-08 2005-04-28 Mieko Katsube Skin liniment
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
WO2009082287A1 (en) * 2007-12-21 2009-07-02 Sca Hgiene Products Ab Absorbent article with odour control substane
EP2331149A1 (en) * 2008-10-03 2011-06-15 Sca Hygiene Products AB Wipe with odour control substance
WO2012168770A1 (en) 2011-06-10 2012-12-13 Universita' Del Salento Process for ozonization of a vegetable oil
WO2022162412A1 (en) 2021-01-29 2022-08-04 Keybiological S.L. Ozonised oil production method, reactor and oil produced

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591602A (en) * 1982-04-16 1986-05-27 James H. Brown Ozonide esters and topical compositions containing same
US4451480A (en) * 1982-04-16 1984-05-29 James Howard Brown Method of treating acne using ozonized materials
US5260342A (en) * 1988-06-24 1993-11-09 Stephen Herman Method for treating viral infection parenterally
WO1989012626A1 (en) * 1988-06-24 1989-12-28 Stephen Herman Ozonides of terpenes and their medical uses
US4983637A (en) * 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV
US5086076A (en) * 1988-06-24 1992-02-04 Stephen Herman Antiviral pharmaceutical compositions comprising a terpene ozonide
US5364879A (en) * 1988-06-24 1994-11-15 Cliveden Ltd. Medical uses of trioxolane and diperoxide compounds
US5126376A (en) * 1988-06-24 1992-06-30 Stephen Herman Method for treating viral infection using topical administration
US5190977A (en) * 1988-06-24 1993-03-02 Stephen Herman Antiviral compositions
US5190979A (en) * 1988-06-24 1993-03-02 Stephen Herman Ozonides of terpenes and their medical uses
US5270344A (en) * 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
WO1990014764A1 (en) * 1989-06-08 1990-12-13 Stephen Herman Method for treating viral infection
US5093326A (en) * 1989-06-19 1992-03-03 Stephen Herman Repellant compositions
WO1993012654A1 (en) * 1991-12-24 1993-07-08 Stephen Herman Medical uses of trioxolane and diperoxide compounds
US5785988A (en) * 1996-05-10 1998-07-28 Fust; Charles A. Composition for freshening nostrils and sinus cavities
US6344210B2 (en) 1996-05-10 2002-02-05 Charles A. Fust Composition for freshening nostrils and sinus cavities
WO2003085072A1 (en) * 2002-04-08 2003-10-16 Centro Nacional De Investigaciones Cientificas (Cnic) Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
JP2005112798A (en) * 2003-10-08 2005-04-28 Atsuya Ogata External therapeutic agent and therapeutic method for treating inflammation or wound of animal
JP2005112796A (en) * 2003-10-08 2005-04-28 Toshiaki Miura Antiinflammatory external preparation
JP2005112797A (en) * 2003-10-08 2005-04-28 Mieko Katsube Skin liniment
US20050084454A1 (en) * 2003-10-14 2005-04-21 Sinofresh Healthcare, Inc. Compositions and methods for cleaning nasal cavities
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
WO2009082287A1 (en) * 2007-12-21 2009-07-02 Sca Hgiene Products Ab Absorbent article with odour control substane
US20100262098A1 (en) * 2007-12-21 2010-10-14 Sca Hygiene Products Ab Absorbent article with odour control substance
AU2007362877B2 (en) * 2007-12-21 2013-07-25 Sca Hgiene Products Ab Absorbent article with odour control substane
US20110150959A1 (en) * 2008-08-21 2011-06-23 Sca Hygiene Products Ab Wipe with odour control substance
EP2331149A1 (en) * 2008-10-03 2011-06-15 Sca Hygiene Products AB Wipe with odour control substance
EP2331149A4 (en) * 2008-10-03 2012-07-11 Sca Hygiene Prod Ab Wipe with odour control substance
WO2012168770A1 (en) 2011-06-10 2012-12-13 Universita' Del Salento Process for ozonization of a vegetable oil
WO2022162412A1 (en) 2021-01-29 2022-08-04 Keybiological S.L. Ozonised oil production method, reactor and oil produced

Similar Documents

Publication Publication Date Title
US2356062A (en) Therapeutic composition
US2496270A (en) Skin dressings with fugitive colors
US2376884A (en) Hydroquinone composition
US3535422A (en) Stable benzoyl peroxide composition
US5190979A (en) Ozonides of terpenes and their medical uses
JPH0212451B2 (en)
CA1338083C (en) Ozonides of terpenes and their medical uses
US1921424A (en) Medicinal remedy
US1947568A (en) Carron oil compound chlorinated cream
US6221403B1 (en) Topical composition
US2436673A (en) Therapeutic peroxide composition
KR910009995B1 (en) Cosmetic composition containing pantetheine-s-sulfonic acid
US2001046A (en) Medicinal preparation
US2451022A (en) Color changing antiseptic composition
US1870107A (en) Medicated ointment composition
GB1424598A (en) Disinfectant
EP0653938B1 (en) Topical composition
De Grosz Local use of vitamin A preparations in ophthalmic practice
DE3049038C2 (en)
US3152951A (en) Germicidal composition of iodine and liquid lanolin
US2281937A (en) Therapeutic composition
US2592149A (en) Therapeutic preparation comprising benzyl cinnamate and vitamin a
DE916208C (en) Process for the preparation of a solution of hexylresorcinol, in particular for pharmaceutical purposes
US1686062A (en) Therapeutic composition
CH575762A5 (en) Rapid-acting oil-in-water disinfectant compsn - is operative at mild pH values